Clinical Trial

A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, multi-regional, multi-center, open-label, first-in-human (FIH), dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of AP402 in HER2-positive patients with locally or advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-31.
Status change: Not Yet Recruiting → Recruiting 2025-04-23
Trial Details
NCT Number NCT06669975
Lead Sponsor AP Biosciences Inc.
Conditions Advanced Solid Tumor
Enrollment 85 participants
Start Date 2025-04-22
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-25